HC Wainwright Forecasts InflaRx’s Q3 Earnings (NASDAQ:IFRX)

InflaRx N.V. (NASDAQ:IFRX) – Investment analysts at HC Wainwright issued their Q3 2026 earnings estimates for shares of InflaRx in a research note issued on Thursday, August 6th. HC Wainwright analyst M. Keller forecasts that the company will earn ($0.09) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for InflaRx’s current full-year earnings is ($0.31) per share. HC Wainwright also issued estimates for InflaRx’s Q4 2026 earnings at ($0.07) EPS, FY2026 earnings at ($0.35) EPS, FY2027 earnings at ($0.36) EPS and FY2028 earnings at ($0.38) EPS.

Other research analysts also recently issued reports about the company. Guggenheim reiterated a “buy” rating and issued a $14.00 price target on shares of InflaRx in a report on Tuesday, April 21st. Cantor Fitzgerald upped their price objective on InflaRx from $4.00 to $6.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Oppenheimer assumed coverage on InflaRx in a research report on Friday, April 24th. They set an “outperform” rating and a $5.00 price objective on the stock. Raymond James Financial upgraded InflaRx from an “outperform” rating to a “strong-buy” rating and lifted their target price for the company from $7.00 to $9.00 in a research note on Wednesday, May 13th. Finally, Zacks Research upgraded shares of InflaRx from a “hold” rating to a “strong-buy” rating in a report on Monday, July 27th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, InflaRx currently has a consensus rating of “Moderate Buy” and an average target price of $7.33.

InflaRx Stock Up 2.0%

InflaRx stock opened at $2.00 on Monday. The business has a fifty day moving average of $1.88 and a two-hundred day moving average of $1.55. The firm has a market cap of $144.58 million, a P/E ratio of -3.45 and a beta of 2.48. InflaRx has a twelve month low of $0.78 and a twelve month high of $2.95.

InflaRx (NASDAQ:IFRX) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.04).

Hedge Funds Weigh In On InflaRx

A number of large investors have recently made changes to their positions in the business. Cubist Systematic Strategies LLC boosted its position in shares of InflaRx by 33.9% in the 1st quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock worth $31,000 after purchasing an additional 7,616 shares in the last quarter. HRT Financial LP acquired a new position in InflaRx during the 4th quarter valued at about $47,000. Concurrent Investment Advisors LLC increased its position in InflaRx by 56.9% during the 4th quarter. Concurrent Investment Advisors LLC now owns 52,951 shares of the company’s stock valued at $53,000 after buying an additional 19,200 shares in the last quarter. Insigneo Advisory Services LLC purchased a new stake in InflaRx in the fourth quarter valued at about $61,000. Finally, Quadrature Capital Ltd purchased a new stake in InflaRx in the fourth quarter valued at about $104,000. 42.39% of the stock is owned by institutional investors and hedge funds.

About InflaRx

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.